MedTrace Logo

Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema

NCT00886808 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2012-03-22

No results posted yet for this study

Summary

The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.

Conditions

  • Diffuse Diabetic Macular Edema

Interventions

DRUG

iCo-007 Intravitreal Injection

single dose iCo-007 Intravitreal Injection

Sponsors & Collaborators

  • iCo Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-05-31
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00886808 on ClinicalTrials.gov